Apyx Medical (APYX) Q2 2026 Earnings Call Transcript

Apyx Medical reported Q2 revenue of $13.9M (+22% YoY), driven by Surgical Aesthetics revenue of $12.4M (+28% YoY), while OEM revenue fell to $1.5M (-12% YoY). Gross margin improved to 63.9% (from 62.3%), but the company still posted an operating loss of $1.8M and net loss attributable to stockholders of $3.2M ($0.07/share). Management reaffirmed FY2026 guidance: total revenue of $59.0M–$60.0M (vs. $52.8M in 2025) and Surgical Aesthetics of $54.0M–$55.0M, assuming gross margin of 62%–63% and operating expenses ≤$45.0M, with Power Lipo shipments and FDA 510(k) clearance supporting growth amid ongoing tariff uncertainty.

Analysis

The market should focus less on reported growth and more on whether APYX is converting from a lumpy capital-equipment story into a repeatable installed-base annuity. Power Lipo matters because it raises per-case economics and increases platform stickiness, but the near-term effect is usually the opposite of what bulls model: first-wave launches typically pressure gross margin, strain supply, and front-load working-capital needs before the recurring tail shows up.

The bigger second-order issue is competitive positioning. If APYX’s all-in-one bundle actually reduces procedure time and improves surgeon throughput, it can win share from narrower aesthetic device vendors like INMD and CUTR, but only in a market that remains discretionary. A slowdown in elective procedures would hit both system placements and consumables, so the thesis is more fragile than the headline growth suggests; the company is also giving up OEM diversification, which makes the equity more dependent on a single commercial narrative.

Over the next 1-3 months, the key catalyst is whether the new attachment product ships without friction and whether attach rates hold near management’s target. Over 6-18 months, the real test is whether recurring per-case revenue plus probe replacement can outgrow the fixed-cost base enough to turn cash burn into self-funding growth. The contrarian view is that the GLP-1 skin-laxity theme may be directionally right but economically too slow to matter in quarterly numbers; if cash burn stays elevated or margins slip below the current range, the story can de-rate quickly.

Key Decisions for Investors

• Do not chase APYX on the first print; wait for Q3 channel checks on Power Lipo shipment cadence and attach rate before considering a long. The setup improves only if the new product converts into sustained consumables pull-through, not just one-time system placements.
• If you want exposure to the aesthetic-device theme, prefer a relative-value pair: long INMD / short APYX on a 1-3 month horizon if APYX rallies into the launch narrative. This captures execution risk without needing a broad slowdown in elective procedures.
• Set an alert on APYX gross margin: a sustained move below 62% would argue the launch is diluting economics faster than the platform is scaling. That would be a clear thesis breaker for any long.
• For aggressive traders only, consider a small, defined-risk APYX call spread into the next operating update if third-quarter shipment data confirms the install base is accelerating. The trade only works if management proves the recurring revenue math is real; otherwise theta decay will punish the position.
• Use cash-burn and working-capital trends as the primary watch item, not revenue growth alone. If quarterly operating cash use stays above roughly $3M and there is no inflection in payback economics, the equity should be treated as a story stock, not a compounding asset.